The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 357:302-303 July 19, 2007 Number 3
NextNext

Interleukin-1–Receptor Antagonist in Type 2 Diabetes Mellitus

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Larsen, C. M.
-PubMed Citation
To the Editor: Larsen et al. (April 12 issue)1 describe salutary changes in many markers of inflammation in patients with type 2 diabetes mellitus treated with anakinra, an interleukin-1–receptor antagonist. They report a significant difference in the glycated hemoglobin level at 13 weeks in the anakinra group as compared with the placebo group, but the mean end-point values in the two groups were in fact identical. Although there was a change from baseline in opposite directions in the two groups, the baseline means were different, so the values in the groups might have been expected to converge somewhat by regression . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.